AKTX

Akari Therapeutics Plc (AKTX) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. Akari Therapeutics Plc is a preclinical oncology company focused on developing next-generation antibody-drug conjugates (ADCs) following its November 2024 merger with Peak Bio, Inc. The company has suspended its legacy nomacopan programs to prioritize the ADC platform. As of the filing date, the company has no approved products and has not generated any revenue.

Key Financial Metrics

Note: Amounts in millions unless otherwise specified. The company reported a net loss per share of $0.00 for both periods due to the large number of outstanding shares.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by 41% ($2.5 million) compared to Q1 2024. This was driven by a 64% reduction in R&D expenses (primarily due to the suspension of the HSCT-TMA clinical program) and a 27% reduction in G&A expenses (lower legal and professional fees).
• Financing Activity: The company executed a March 2025 Private Placement. Gross proceeds were approximately $6.6 million, with $1.0 million satisfied via debt-to-equity conversion with the Chairman. Approximately $4.0 million of cash proceeds were received in April 2025 (subsequent to the period end).
• Debt Management: The company settled a $0.4 million note in March 2025 for $0.325 million, recognizing a gain on debt extinguishment of less than $0.1 million.
• Warrant Liability: The fair value of warrant liabilities increased by $0.054 million, resulting in a non-cash loss, compared to a $0.649 million non-cash gain in Q1 2024.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. As of March 31, 2025, cash of $2.6 million is insufficient to fund operations for the next 12 months. Including subsequent cash receipts of $4.0 million, management estimates funds are sufficient only through September 2025.
• Capital Needs: The company must raise additional capital to continue operations. Strategies include equity/debt financings, strategic collaborations, or licensing. Failure to secure funding could result in delayed development, asset sales, or cessation of operations.
• Leadership Change: Mr. Abizer Gaslightwala was appointed President and CEO, effective April 21, 2025.
• Internal Controls: The company disclosed material weaknesses in internal control over financial reporting as of December 31, 2024, which remained unremediated as of March 31, 2025. Remediation efforts are expected to begin in Q3 2025.
• Legal Proceedings: The company settled a wrongful termination claim with a former consultant for $0.3 million and reached a settlement regarding a warrant exercise dispute with "Sabby" Volatility Warrant Master Fund Ltd.

Investor Verification Checklist

• Cash Runway: Verify the exact date by which current cash (including the $4.0M subsequent receipt) will be exhausted and the status of any new financing discussions.
• Debt Obligations: Review the terms of the assumed Peak Bio debt (approx. $1.6M principal) and related party notes to understand immediate repayment pressures.
• Warrant Liability Volatility: Monitor the fair value of the $1.1 million in liability-classified warrants, as fluctuations significantly impact reported net loss.
• Internal Control Remediation: Track the progress of the remediation plan for material weaknesses in financial reporting controls.
• Pipeline Progress: Confirm the status of the lead ADC candidate (AKTX-101) and any potential licensing deals for the PHP-303 program to generate non-dilutive revenue.